Trial · NCT01752049
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
NCT01752049, Phase 1, Phase 2, Completed, Unity Health Toronto; results first posted 2023-09-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept. Trials, record NCT01752049. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01752049
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
- NCT number
- NCT01752049
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Unity Health Toronto
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Topical timolol maleate, placebo saline drops
- First posted
- 2012-12-18
- Last updated
- 2023-09-21
- Results first posted
- 2023-09-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Lesion Area of Treated Telangiectasia. | 84 days | Change in lesion area (compared with baseline measurement) of treated telangiectasia. |
| Secondary | Descriptive Changes in Histopathology in Baseline vs Treated Lesions | 84 days | |
| Secondary | Serum Angiogenic Markers | 84 days | |
| Secondary | Stability of Area of Untreated Telangiectasias Over the 84 Day Period | 84 days | |
| Secondary | Blood Flow Velocity and Volume Flow Rates | 84 days |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Lesion Area of Treated Telangiectasia. | 84 days | 5 participants enrolled, each participant have Hereditary Hemorrhagic Telangiectasia (HHT) and have at least 5 typical telangiectasias on their hands or face. | mm^2 | GEOMETRIC_MEAN |
| SECONDARY | Descriptive Changes in Histopathology in Baseline vs Treated Lesions | 84 days | No data collected | ||
| SECONDARY | Serum Angiogenic Markers | 84 days | No data collected | ||
| SECONDARY | Stability of Area of Untreated Telangiectasias Over the 84 Day Period | 84 days | No data collected | ||
| SECONDARY | Blood Flow Velocity and Volume Flow Rates | 84 days | No data collected |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Lesion Area of Treated Telangiectasia. | Topical Timolol Maleate | -6 | Standard Deviation 11 | mm^2 | |
| Change in Lesion Area of Treated Telangiectasia. | Placebo | -8 | Standard Deviation 17 | mm^2 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topical Timolol Maleate | 5 | 15 |
| Overall Study | STARTED | Placebo | 5 | 5 |
| Overall Study | COMPLETED | Topical Timolol Maleate | 5 | 15 |
| Overall Study | COMPLETED | Placebo | 5 | 5 |
| Overall Study | NOT COMPLETED | Topical Timolol Maleate | 0 | 0 |
| Overall Study | NOT COMPLETED | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Minor infection at biopsy site | Skin and subcutaneous tissue disorders | Topical Timolol Maleate | 1 | 5 | 1 |
| other | Minor infection at biopsy site | Skin and subcutaneous tissue disorders | Placebo | 1 | 5 | 1 |
| other | Minor bleeding at biopsy site | Skin and subcutaneous tissue disorders | Topical Timolol Maleate | 1 | 5 | 1 |
| other | Minor bleeding at biopsy site | Skin and subcutaneous tissue disorders | Placebo | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topical Timolol Maleate | 0 | 5 |
| Total, all-cause mortality | Placebo | 0 | 5 |
| Total, other adverse events | Topical Timolol Maleate | 1 | 5 |
| Total, other adverse events | Placebo | 1 | 5 |
| Total, serious adverse events | Topical Timolol Maleate | 0 | 5 |
| Total, serious adverse events | Placebo | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U54NS065705 | Brain Vascular Malformation Consortium: Predictor's of Clinical Course | KIM, HELEN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2009 to 2023 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Topical Timolol Maleate vs Placebo: deaths from any cause | Trial comparisons |
| Topical Timolol Maleate vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01752049
GET https://conductscience.org/api/trials/v1/NCT01752049/registered